Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) Shares Outstanding (Diluted Average) (2021 - 2026)

Wave Life Sciences (WVE) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $200.2 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) rose 23.13% year-over-year to $200.2 million; the TTM value through Mar 2026 reached $200.2 million, up 23.13%, while the annual FY2025 figure was $168.6 million, 21.96% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $200.2 million in Q1 2026 for Wave Life Sciences, up from $168.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $200.2 million in Q1 2026 and bottomed at $60.5 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $123.9 million, with a median of $129.3 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Diluted Average) soared 68.64% in 2023 and then grew 21.96% in 2025.
  • Wave Life Sciences' Shares Outstanding (Diluted Average) stood at $78.9 million in 2022, then surged by 34.55% to $106.1 million in 2023, then surged by 30.33% to $138.3 million in 2024, then increased by 21.96% to $168.6 million in 2025, then increased by 18.69% to $200.2 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $200.2 million, $168.6 million, and $167.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.